Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310908 | 1.00 | MAPT (0.38) | MAPTGAAALDH1A1TP53TSHR | |
| Fluoride Ion SCHEMBL29695344 | 0.96 | MAPT (0.35) | MAPTGAAALDH1A1TP53TSHR | |
| SCHEMBL19713586 | 0.92 | MAPT (0.33) | MAPTGAAALDH1A1TP53TSHR | |
| SCHEMBL2850702 | 0.87 | — | — | |
| SCHEMBL29406125 | 0.84 | MAPT (0.37) | MAPTGAAALDH1A1TP53TSHR | |
| SCHEMBL238097 | 0.84 | MAPT (0.37) | MAPTGAAALDH1A1TP53TSHR | |
| SCHEMBL28888541 | 0.79 | MAPT (0.35) | MAPTGAAALDH1A1TP53TSHR | |
| SCHEMBL1315082 | 0.78 | MAPK1 (0.32) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL30480018 | 0.78 | MAPK1 (0.32) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL2852135 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423764-A | Intermediate, preparation method and application thereof | 四川大学 | 2022-04-29 | — | — | CN | claimed |
| US-6686495-B2 | IN PRESENCE OF PALLADIUM CATALYST; USEFUL IN PRODUCING CHEMICAL INTERMEDIATES FOR PHARMACEUTICALS, OPTICAL BRIGHTENING AGENTS AND AGROCHEMICALS | OMG AG & CO KG (DE) | 2004-02-03 | — | — | US | claimed |
| US-20020107426-A1 | Process for the preparation of mono-, bi- or poly- functional biaryls | UMICORE AG & CO. KG (DE) | 2002-08-08 | — | — | US | claimed |
| EP-1199292-A1 | Process for the production of mono-, bi- or polyfunctional biaryls | OMG AG & Co. KG (DE) | 2002-04-24 | — | — | EP | claimed |
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | BHATTACHARYA SHRABANTI (US) | 2025-12-04 | — | — | US | disclosed |
| CN-119998255-A | Catalytic carboxycarbonylation of olefins to form anhydrides | 北卡罗来纳大学教堂山分校 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025064802-A1 | INHIBITING HUMAN INTEGRIN α5β1 | MORPHIC THERAPEUTIC, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240424116-A1 | Pegylated-AU(III) Reagents for Rapid Cysteine S-Arylation of Biomolecules | UNIV CALIFORNIA (US) | 2024-12-26 | — | — | US | disclosed |
| US-12030882-B2 | Crystalline solid forms of a bet inhibitor | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11911751-B2 | Catalyst compositions for hydroformylation and methods of use thereof | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-07-04 | — | — | US | disclosed |
| CN-106163523-A | Solid forms of 2- (tert-butylamino) -4- ((1R,3R,4R) -3-hydroxy-4-methylcyclohexylamino) -pyrimidine-5-carboxamide, compositions thereof, and methods of use thereof | 西格诺药品有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20130253185-A1 | NOVEL CATALYSTS | DALHOUSIE UNIVERSITY (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130253185-A1 | NOVEL CATALYSTS | DALHOUSIE UNIVERSITY (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130253185-A1 | NOVEL CATALYSTS | DALHOUSIE UNIVERSITY (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2012068335-A2 | NOVEL CATALYSTS | DALHOUSIE UNIVERSITY (CA) | 2012-05-24 | — | — | WO | disclosed |
| US-6686495-B2 | IN PRESENCE OF PALLADIUM CATALYST; USEFUL IN PRODUCING CHEMICAL INTERMEDIATES FOR PHARMACEUTICALS, OPTICAL BRIGHTENING AGENTS AND AGROCHEMICALS | OMG AG & CO KG (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20020107426-A1 | Process for the preparation of mono-, bi- or poly- functional biaryls | UMICORE AG & CO. KG (DE) | 2002-08-08 | — | — | US | disclosed |
| EP-1199292-A1 | Process for the production of mono-, bi- or polyfunctional biaryls | OMG AG & Co. KG (DE) | 2002-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368598-A1 | CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES | CA4, CA12, CA14 | MAPT 4193/4885GAA 1208/4885ALDH1A1 688/4885 |
| US-12030882-B2 | Crystalline solid forms of a bet inhibitor | BRD1, BRD3, BRD2 | MAPT 612/4885GAA 3385/4885ALDH1A1 4804/4885 |
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | MAPT 2148/4885GAA 548/4885ALDH1A1 2016/4885 |
| US-20240424116-A1 | Pegylated-AU(III) Reagents for Rapid Cysteine S-Arylation of Biomolecules | LNPEP, PTMS, EGFR | MAPT 2258/4885GAA 2192/4885ALDH1A1 2594/4885 |
| US-11691946-B2 | Preparation of Trifarotene and intermediates and polymorphs thereof | UGT1A4, TBK1, UGT1A7 | MAPT 2148/4885GAA 548/4885ALDH1A1 2016/4885 |
| US-20020107426-A1 | Process for the preparation of mono-, bi- or poly- functional biaryls | CYP4F3, CYP4F2, CYP2F1 | MAPT 3645/4885GAA 187/4885ALDH1A1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.